Home
Clinical Trials
NCT00480025

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer

Last Updated: 2020-12-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

2278 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-04

Study Completion Date

2014-09-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical trial is to demonstrate the benefit of the immunotherapeutic product GSK1572932A when given to patients with Non-Small Cell Lung Cancer, after removal of their tumor. A course of 13 injections will be administered over 27 months. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer, Non-Small Cell

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

ASCI Immunotherapeutic MAGRIT Tumor antigen Non-small-cell lung cancer Adjuvant cancer therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GSK1572932 Group

Patients received up to 13 doses of GSK1572932, 5 doses every 3 weeks followed by 8 doses every 12 weeks.

Group Type EXPERIMENTAL

GSK1572932A Antigen-Specific Cancer Immunotherapeutic

Intervention Type BIOLOGICAL

Intramuscular administration, 13 doses

Placebo Group

Patients received up to 13 doses of placebo, 5 doses every 3 weeks followed by 8 doses every 12 weeks.

Group Type PLACEBO_COMPARATOR

Placebo Control

Intervention Type BIOLOGICAL

Intramuscular administration, 13 doses

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GSK1572932A Antigen-Specific Cancer Immunotherapeutic

Intramuscular administration, 13 doses

Intervention Type BIOLOGICAL

Placebo Control

Intramuscular administration, 13 doses

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patient with completely resected, pathologically proven stage IB, II or IIIA NSCLC.
* Written informed consent for MAGE-A3 expression screening on tumor biopsy has been obtained from the patient prior to shipment of the sample for expression testing (before or just after surgical resection), and written informed consent for the complete study has been obtained prior to the performance of any other protocol-specific procedure.
* Patient is ≥ 18 years of age at the time of signature of the first informed consent form.
* The patient's tumor shows expression of MAGE-A3 gene
* The surgical technique for resection of the patient's tumor is anatomical, involving at least a lobectomy or a sleeve lobectomy;
* The mediastinal lymph node sampling is done according to study protocol guidelines;
* The patient is free of metastasis, as confirmed by a negative baseline computer tomogram (CT scan) of the chest, upper abdomen and CT scan or MRI of the brain.

Other examinations should be performed as clinically indicated. Note that if randomization is taking place within 8 weeks after surgery, brain CT scans or brain MRI performed up to 4 weeks before surgery do not have to be repeated.

* ECOG performance status of 0, 1 or 2 at the time of randomization.
* Adequate bone-marrow reserve, adequate renal function and adequate hepatic function as assessed by standard laboratory criteria, and defined as:

Absolute neutrophil count ≥ 1.0 x 10E9/L Platelet count ≥ 75 x 10E9/L Serum creatinine ≤ 1.5 times the Upper Limit of Normal (ULN)

≤ 3.0 times the ULN if due to platinum adjuvant chemotherapy Total bilirubin ≤ 1.5 times the ULN Alanine transaminase (ALAT) ≤ 2.5 times the ULN

* If the patient is female, she must be of non-childbearing potential, i.e. have a current tubal ligation, hysterectomy, ovariectomy or be post menopausal, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to administration of study treatment, have a negative pregnancy test and continue such precautions during all study treatment period and for 2 months after completion of the injection series.
* In the view of the investigator, the patient can and will comply with the requirements of the protocol.

Exclusion Criteria

* The primary tumor was removed by segmentectomy or wedge resection.
* The patient shows any evidence of residual tumor after surgery.
* The patient has received any anti-cancer specific treatment, including radiotherapy, immunotherapy, chemotherapy or neo-adjuvant chemotherapy, except:

For the treatment of previous malignancies as allowed by the protocol (i.e., non-melanoma skin cancers or carcinoma in situ of the cervix or effectively treated malignancy that has been in remission for over 5 years), Administration of adjuvant platinum-based chemotherapy for the treatment of the current NSCLC is allowed between surgery and randomization.

* The patient has previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers or carcinoma in situ of the cervix or effectively treated malignancy that has been in remission for over 5 years and highly likely to have been cured.
* History of allergic disease or reactions likely to be exacerbated by any component of the study investigational product.
* The patient has an autoimmune disease such as, but not limited to, multiple sclerosis, lupus, and inflammatory bowel disease. Patients with vitiligo are not excluded.
* The patient requires concomitant treatment with systemic corticosteroids, or any other immunosuppressive agents.

Note: The use of prednisone, or equivalent, \<0.5 mg/kg/day (absolute maximum 40 mg/day), or inhaled corticosteroids for COPD or topical steroids is permitted.

* The patient has received a major organ allograft.
* The patient is known to be HIV-positive.
* The patient has an uncontrolled bleeding disorder.
* The patient has uncontrolled congestive heart failure or hypertension, unstable heart disease (coronary artery disease or myocardial infarction) or uncontrolled arrhythmia at the time of enrolment.
* The patient needs home oxygenation.
* The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent, or to comply with the trial procedures.
* The patient has other concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.
* The patient has received any investigational or non-registered medicinal product other than the study medication within the 30 days preceding the first dose of study medication, or plans to receive such a drug during the study period.
* For female patients: the patient is pregnant or lactating.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Vinnytsia, , Ukraine

Site Status

GSK Investigational Site

Birmingham, Alabama, United States

Site Status

GSK Investigational Site

Mobile, Alabama, United States

Site Status

GSK Investigational Site

Mobile, Alabama, United States

Site Status

GSK Investigational Site

Phoenix, Arizona, United States

Site Status

GSK Investigational Site

Scottsdale, Arizona, United States

Site Status

GSK Investigational Site

Scottsdale, Arizona, United States

Site Status

GSK Investigational Site

Tucson, Arizona, United States

Site Status

GSK Investigational Site

Fayetteville, Arkansas, United States

Site Status

GSK Investigational Site

Fort Smith, Arkansas, United States

Site Status

GSK Investigational Site

Jonesboro, Arkansas, United States

Site Status

GSK Investigational Site

Bakersfield, California, United States

Site Status

GSK Investigational Site

Beverly Hills, California, United States

Site Status

GSK Investigational Site

Burbank, California, United States

Site Status

GSK Investigational Site

Duarte, California, United States

Site Status

GSK Investigational Site

Fresno, California, United States

Site Status

GSK Investigational Site

Greenbrae, California, United States

Site Status

GSK Investigational Site

La Jolla, California, United States

Site Status

GSK Investigational Site

La Jolla, California, United States

Site Status

GSK Investigational Site

Los Angeles, California, United States

Site Status

GSK Investigational Site

Montebello, California, United States

Site Status

GSK Investigational Site

Orange, California, United States

Site Status

GSK Investigational Site

Palm Springs, California, United States

Site Status

GSK Investigational Site

Palo Alto, California, United States

Site Status

GSK Investigational Site

Pleasant Hill, California, United States

Site Status

GSK Investigational Site

Rancho Mirage, California, United States

Site Status

GSK Investigational Site

Sacramento, California, United States

Site Status

GSK Investigational Site

Sacramento, California, United States

Site Status

GSK Investigational Site

San Diego, California, United States

Site Status

GSK Investigational Site

San Diego, California, United States

Site Status

GSK Investigational Site

San Francisco, California, United States

Site Status

GSK Investigational Site

Santa Rosa, California, United States

Site Status

GSK Investigational Site

Stanford, California, United States

Site Status

GSK Investigational Site

Vallejo, California, United States

Site Status

GSK Investigational Site

West Hollywood, California, United States

Site Status

GSK Investigational Site

Aurora, Colorado, United States

Site Status

GSK Investigational Site

Colorado Springs, Colorado, United States

Site Status

GSK Investigational Site

Danbury, Connecticut, United States

Site Status

GSK Investigational Site

Torrington, Connecticut, United States

Site Status

GSK Investigational Site

Waterbury, Connecticut, United States

Site Status

GSK Investigational Site

Newark, Delaware, United States

Site Status

GSK Investigational Site

Washington D.C., District of Columbia, United States

Site Status

GSK Investigational Site

Boca Raton, Florida, United States

Site Status

GSK Investigational Site

Boynton Beach, Florida, United States

Site Status

GSK Investigational Site

Deerfield Beach, Florida, United States

Site Status

GSK Investigational Site

Fort Lauderdale, Florida, United States

Site Status

GSK Investigational Site

Hollywood, Florida, United States

Site Status

GSK Investigational Site

Jacksonville, Florida, United States

Site Status

GSK Investigational Site

Ocala, Florida, United States

Site Status

GSK Investigational Site

Orlando, Florida, United States

Site Status

GSK Investigational Site

Orlando, Florida, United States

Site Status

GSK Investigational Site

Stuart, Florida, United States

Site Status

GSK Investigational Site

Tampa, Florida, United States

Site Status

GSK Investigational Site

West Palm Beach, Florida, United States

Site Status

GSK Investigational Site

Alpharetta, Georgia, United States

Site Status

GSK Investigational Site

Athens, Georgia, United States

Site Status

GSK Investigational Site

Atlanta, Georgia, United States

Site Status

GSK Investigational Site

Atlanta, Georgia, United States

Site Status

GSK Investigational Site

Atlanta, Georgia, United States

Site Status

GSK Investigational Site

Augusta, Georgia, United States

Site Status

GSK Investigational Site

Macon, Georgia, United States

Site Status

GSK Investigational Site

Marietta, Georgia, United States

Site Status

GSK Investigational Site

Savannah, Georgia, United States

Site Status

GSK Investigational Site

Honolulu, Hawaii, United States

Site Status

GSK Investigational Site

Coeur d'Alene, Idaho, United States

Site Status

GSK Investigational Site

Chicago, Illinois, United States

Site Status

GSK Investigational Site

Chicago, Illinois, United States

Site Status

GSK Investigational Site

Chicago, Illinois, United States

Site Status

GSK Investigational Site

Decatur, Illinois, United States

Site Status

GSK Investigational Site

Evanston, Illinois, United States

Site Status

GSK Investigational Site

Harvey, Illinois, United States

Site Status

GSK Investigational Site

Park Ridge, Illinois, United States

Site Status

GSK Investigational Site

Peoria, Illinois, United States

Site Status

GSK Investigational Site

Springfield, Illinois, United States

Site Status

GSK Investigational Site

Evansville, Indiana, United States

Site Status

GSK Investigational Site

Indianapolis, Indiana, United States

Site Status

GSK Investigational Site

Indianapolis, Indiana, United States

Site Status

GSK Investigational Site

Munster, Indiana, United States

Site Status

GSK Investigational Site

New Albany, Indiana, United States

Site Status

GSK Investigational Site

Waterloo, Iowa, United States

Site Status

GSK Investigational Site

Ashland, Kentucky, United States

Site Status

GSK Investigational Site

Hazard, Kentucky, United States

Site Status

GSK Investigational Site

Lexington, Kentucky, United States

Site Status

GSK Investigational Site

Louisville, Kentucky, United States

Site Status

GSK Investigational Site

Owensboro, Kentucky, United States

Site Status

GSK Investigational Site

Alexandria, Louisiana, United States

Site Status

GSK Investigational Site

Metairie, Louisiana, United States

Site Status

GSK Investigational Site

Shreveport, Louisiana, United States

Site Status

GSK Investigational Site

Annapolis, Maryland, United States

Site Status

GSK Investigational Site

Baltimore, Maryland, United States

Site Status

GSK Investigational Site

Baltimore, Maryland, United States

Site Status

GSK Investigational Site

Baltimore, Maryland, United States

Site Status

GSK Investigational Site

Baltimore, Maryland, United States

Site Status

GSK Investigational Site

Bethesda, Maryland, United States

Site Status

GSK Investigational Site

Silver Spring, Maryland, United States

Site Status

GSK Investigational Site

Towson, Maryland, United States

Site Status

GSK Investigational Site

Boston, Massachusetts, United States

Site Status

GSK Investigational Site

Boston, Massachusetts, United States

Site Status

GSK Investigational Site

Boston, Massachusetts, United States

Site Status

GSK Investigational Site

Worcester, Massachusetts, United States

Site Status

GSK Investigational Site

Worcester, Massachusetts, United States

Site Status

GSK Investigational Site

Ann Arbor, Michigan, United States

Site Status

GSK Investigational Site

Bay City, Michigan, United States

Site Status

GSK Investigational Site

Detroit, Michigan, United States

Site Status

GSK Investigational Site

Detroit, Michigan, United States

Site Status

GSK Investigational Site

Flint, Michigan, United States

Site Status

GSK Investigational Site

Grand Rapids, Michigan, United States

Site Status

GSK Investigational Site

Lansing, Michigan, United States

Site Status

GSK Investigational Site

Lapeer, Michigan, United States

Site Status

GSK Investigational Site

Southfield, Michigan, United States

Site Status

GSK Investigational Site

Minneapolis, Minnesota, United States

Site Status

GSK Investigational Site

Minneapolis, Minnesota, United States

Site Status

GSK Investigational Site

Rochester, Minnesota, United States

Site Status

GSK Investigational Site

Saint Louis Park, Minnesota, United States

Site Status

GSK Investigational Site

Saint Louis Park, Minnesota, United States

Site Status

GSK Investigational Site

Kansas City, Missouri, United States

Site Status

GSK Investigational Site

Kansas City, Missouri, United States

Site Status

GSK Investigational Site

Springfield, Missouri, United States

Site Status

GSK Investigational Site

St Louis, Missouri, United States

Site Status

GSK Investigational Site

Billings, Montana, United States

Site Status

GSK Investigational Site

Grand Island, Nebraska, United States

Site Status

GSK Investigational Site

Omaha, Nebraska, United States

Site Status

GSK Investigational Site

Henderson, Nevada, United States

Site Status

GSK Investigational Site

Lebanon, New Hampshire, United States

Site Status

GSK Investigational Site

Long Branch, New Jersey, United States

Site Status

GSK Investigational Site

Paramus, New Jersey, United States

Site Status

GSK Investigational Site

Armonk, New York, United States

Site Status

GSK Investigational Site

Buffalo, New York, United States

Site Status

GSK Investigational Site

East Syracuse, New York, United States

Site Status

GSK Investigational Site

Flushing, New York, United States

Site Status